July 24 (Reuters) - Immuron Ltd IMC.AX :
* US DEPARTMENT OF DEFENSE RESEARCH COLLABORATION MOVES FORWARD
* IMMURON LTD - PROGRAMS NOW ADVANCE TO EVALUATE THERAPEUTIC EFFICACY OF TRAVELAN IN PRE-CLINICAL SHIGELLOSIS CHALLENGE STUDIES
* IMMURON LTD - RESEARCH AGREEMENT WITH CSIRO TO DEVELOP SHIGELLA SPECIFIC ANTI-MICROBIAL THERAPEUTICS FOR PRECLINICAL EVALUATION
* IMMURON LTD - PREVENTATIVE TREATMENT THAT PROTECTS AGAINST ENTERIC DISEASES, SPECIFICALLY SHIGELLA, IS HIGH PRIORITY OBJECTIVE FOR US ARMY
* IMMURON LTD - STUDIES COMMISSIONED BY US DEPARTMENT OF DEFENSE TO EVALUATE TRAVELAN'S ABILITY TO NEUTRALISE PATHOGENIC BACTERIA OF INTEREST
* IMMURON LTD - THREE US DEFENSE HEALTH FUNDED RESEARCH PROJECTS ON TRAVELAN SUCCESSFULLY COMPLETED